Jazz Pharmaceuticals Public Limited Company provided earnings guidance for the fiscal year 2017 and 2018. For the fiscal year 2017, the company expects to revenues will fall within its previously given guidance of $1.6 billion to $1.65 billion. Adjusted net income guidance of $655 million to $685 million would represent dropping more than 40% of the top line revenue all the way through to after-tax income, providing the company with excellent cash flow. Net income to per share guidance of $10.70 to $11.20 per share. The company estimate a decrease in tax rate in the mid-single-digits for 2018.